Found: 6
Select item for more details and to access through your institution.
Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients.
- Published in:
- International Urology & Nephrology, 2019, v. 51, n. 9, p. 1623, doi. 10.1007/s11255-019-02180-8
- By:
- Publication type:
- Article
Effects of the sodium‐glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
- Published in:
- Nephrology, 2019, v. 24, n. 9, p. 904, doi. 10.1111/nep.13552
- By:
- Publication type:
- Article
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease.
- Published in:
- Diabetology & Metabolic Syndrome, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13098-020-00545-z
- By:
- Publication type:
- Article
Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial.
- Published in:
- Frontiers in Medicine, 2023, p. 1, doi. 10.3389/fmed.2023.1287066
- By:
- Publication type:
- Article
Sodium–Glucose Cotransporter 2 Inhibitor Combined with Conventional Diuretics Ameliorate Body Fluid Retention without Excessive Plasma Volume Reduction.
- Published in:
- Diagnostics (2075-4418), 2024, v. 14, n. 11, p. 1194, doi. 10.3390/diagnostics14111194
- By:
- Publication type:
- Article
Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease.
- Published in:
- PLoS ONE, 2017, v. 12, n. 6, p. 1, doi. 10.1371/journal.pone.0178971
- By:
- Publication type:
- Article